marketcaparena
Search

    ABBV

    AbbVie Inc.

    Company overview

    Market capitalization
    $470.55B
    Employees
    57,000
    Latest publication
    2026-09-29
    About AbbVie Inc.

    AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

    Company website

    Financial statements

    Income YTD

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USD
    Total Revenue31,992,000,000USD
    Cost Of Revenue8,509,000,000USD
    Gross Profit23,483,000,000USD
    Research Development4,816,000,000USD
    Selling General Administrative7,210,000,000USD
    Other Operating Expenses1,035,000,000USD
    Total Operating Expenses13,061,000,000USD
    Operating Income10,422,000,000USD
    Total Other Income Expense Net-5,105,000,000USD
    Interest Income139,000,000USD
    Interest Expense1,463,000,000USD
    Income Before Tax5,317,000,000USD
    Income Tax Expense1,004,000,000USD
    Net Income4,313,000,000USD
    Minority Interest5,000,000USD
    Net Income Applicable To Common Shares4,308,000,000USD
    SourceDisclosureDeterministicFinal

    Income Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USDQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ3 20242024-09-30 · USDQ2 20242024-06-30 · USDQ1 20242024-03-31 · USD
    Total Revenue16,990,000,000USD15,002,000,000USD16,618,000,000USD15,423,000,000USD13,343,000,000USD14,460,000,000USD14,462,000,000USD12,310,000,000USD
    Cost Of Revenue4,291,000,000USD4,218,000,000USD4,552,000,000USD4,346,000,000USD4,002,000,000USD4,212,000,000USD4,202,000,000USD4,094,000,000USD
    Gross Profit12,699,000,000USD10,784,000,000USD12,066,000,000USD11,077,000,000USD9,341,000,000USD10,248,000,000USD10,260,000,000USD8,216,000,000USD
    Research Development2,344,000,000USD2,472,000,000USD2,579,000,000USD2,131,000,000USD2,067,000,000USD2,130,000,000USD1,948,000,000USD1,939,000,000USD
    Selling General Administrative3,632,000,000USD3,578,000,000USD3,895,000,000USD3,253,000,000USD3,293,000,000USD4,205,000,000USD3,377,000,000USD3,315,000,000USD
    Other Operating Expenses291,000,000USD———————
    Total Operating Expenses6,267,000,000USD6,794,000,000USD6,257,000,000USD6,183,000,000USD5,608,000,000USD6,417,000,000USD6,262,000,000USD5,418,000,000USD
    Operating Income6,432,000,000USD3,990,000,000USD5,809,000,000USD4,894,000,000USD3,733,000,000USD3,831,000,000USD3,998,000,000USD2,798,000,000USD
    Total Other Income Expense Net-2,154,000,000USD-2,951,000,000USD-3,141,000,000USD-3,340,000,000USD-2,072,000,000USD-1,747,000,000USD-1,852,000,000USD-1,043,000,000USD
    Interest Income67,000,000USD72,000,000USD59,000,000USD62,000,000USD73,000,000USD129,000,000USD220,000,000USD207,000,000USD
    Interest Expense746,000,000USD717,000,000USD714,000,000USD740,000,000USD700,000,000USD720,000,000USD726,000,000USD660,000,000USD
    Income Before Tax4,278,000,000USD1,039,000,000USD2,668,000,000USD1,554,000,000USD1,661,000,000USD2,084,000,000USD2,146,000,000USD1,755,000,000USD
    Income Tax Expense662,000,000USD342,000,000USD853,000,000USD613,000,000USD372,000,000USD520,000,000USD773,000,000USD383,000,000USD
    Net Income3,616,000,000USD697,000,000USD1,816,000,000USD938,000,000USD1,286,000,000USD1,561,000,000USD1,370,000,000USD1,369,000,000USD
    Minority Interest3,000,000USD2,000,000USD1,000,000USD-3,000,000USD-3,000,000USD-3,000,000USD-3,000,000USD-3,000,000USD
    Net Income Applicable To Common Shares3,613,000,000USD685,000,000USD——————
    Unclassified Operating Expenses——-217,000,000USD799,000,000USD248,000,000USD82,000,000USD937,000,000USD164,000,000USD
    Net Interest Income——-655,000,000USD-678,000,000USD-627,000,000USD-591,000,000USD-506,000,000USD-453,000,000USD
    Tax Provision——853,000,000USD613,000,000USD372,000,000USD520,000,000USD773,000,000USD383,000,000USD
    Net Income From Continuing Ops——1,815,000,000USD941,000,000USD1,289,000,000USD1,564,000,000USD1,373,000,000USD1,372,000,000USD
    Ebit——3,382,000,000USD2,294,000,000USD2,361,000,000USD2,804,000,000USD2,872,000,000USD2,415,000,000USD
    Ebitda——5,369,000,000USD4,344,000,000USD4,400,000,000USD4,883,000,000USD5,003,000,000USD4,489,000,000USD
    Depreciation And Amortization——1,987,000,000USD2,050,000,000USD2,039,000,000USD2,079,000,000USD2,131,000,000USD2,074,000,000USD
    Reconciled Depreciation——1,987,000,000USD2,050,000,000USD2,039,000,000USD2,079,000,000USD2,131,000,000USD2,074,000,000USD
    SourceDisclosureDeterministicFinalDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Income Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Total Revenue61,160,000,000USD56,334,000,000USD54,318,000,000USD58,054,000,000USD56,197,000,000USD45,804,000,000USD33,266,000,000USD32,753,000,000USD
    Cost Of Revenue18,204,000,000USD16,904,000,000USD20,415,000,000USD17,414,000,000USD17,446,000,000USD15,387,000,000USD7,439,000,000USD7,718,000,000USD
    Gross Profit42,956,000,000USD39,430,000,000USD33,903,000,000USD40,640,000,000USD38,751,000,000USD30,417,000,000USD25,827,000,000USD25,035,000,000USD
    Research Development9,096,000,000USD12,791,000,000USD7,675,000,000USD6,510,000,000USD8,046,000,000USD7,755,000,000USD6,792,000,000USD10,753,000,000USD
    Selling General Administrative14,010,000,000USD11,089,000,000USD10,704,000,000USD13,260,000,000USD10,249,000,000USD8,067,000,000USD5,842,000,000USD6,253,000,000USD
    Unclassified Operating Expenses-241,000,000USD4,313,000,000USD567,000,000USD753,000,000USD432,000,000USD1,432,000,000USD210,000,000USD546,000,000USD
    Total Operating Expenses22,865,000,000USD30,293,000,000USD21,146,000,000USD22,523,000,000USD20,827,000,000USD19,054,000,000USD12,844,000,000USD18,652,000,000USD
    Operating Income20,091,000,000USD9,137,000,000USD12,757,000,000USD18,117,000,000USD17,924,000,000USD11,363,000,000USD12,983,000,000USD6,383,000,000USD
    Interest Income266,000,000USD648,000,000USD540,000,000USD186,000,000USD39,000,000USD174,000,000USD275,000,000USD204,000,000USD
    Interest Expense2,893,000,000USD2,808,000,000USD2,224,000,000USD2,230,000,000USD2,423,000,000USD2,454,000,000USD1,784,000,000USD1,348,000,000USD
    Net Interest Income-2,627,000,000USD-2,160,000,000USD-1,684,000,000USD-2,044,000,000USD-2,384,000,000USD-2,280,000,000USD-1,509,000,000USD-1,144,000,000USD
    Income Before Tax6,597,000,000USD3,716,000,000USD6,250,000,000USD13,477,000,000USD12,989,000,000USD3,398,000,000USD8,426,000,000USD5,197,000,000USD
    Income Tax Expense2,364,000,000USD-570,000,000USD1,377,000,000USD1,632,000,000USD1,440,000,000USD-1,224,000,000USD544,000,000USD-490,000,000USD
    Tax Provision2,364,000,000USD-570,000,000USD1,377,000,000USD1,632,000,000USD1,440,000,000USD-1,224,000,000USD544,000,000USD-490,000,000USD
    Net Income4,226,000,000USD4,278,000,000USD4,863,000,000USD11,836,000,000USD11,542,000,000USD4,616,000,000USD7,882,000,000USD5,687,000,000USD
    Net Income From Continuing Ops4,233,000,000USD4,286,000,000USD4,873,000,000USD11,845,000,000USD11,549,000,000USD4,622,000,000USD7,882,000,000USD5,687,000,000USD
    Ebit9,490,000,000USD6,524,000,000USD8,474,000,000USD15,707,000,000USD15,412,000,000USD5,852,000,000USD10,210,000,000USD6,545,000,000USD
    Ebitda17,629,000,000USD14,910,000,000USD17,172,000,000USD24,174,000,000USD23,933,000,000USD12,323,000,000USD12,227,000,000USD8,310,000,000USD
    Depreciation And Amortization8,139,000,000USD8,386,000,000USD8,698,000,000USD8,467,000,000USD8,521,000,000USD6,471,000,000USD2,017,000,000USD1,765,000,000USD
    Reconciled Depreciation8,139,000,000USD8,386,000,000USD8,698,000,000USD8,467,000,000USD8,521,000,000USD6,471,000,000USD2,017,000,000USD1,765,000,000USD
    Total Other Income Expense Net-13,494,000,000USD-5,421,000,000USD-6,507,000,000USD-4,640,000,000USD-4,935,000,000USD-7,965,000,000USD-4,557,000,000USD-1,186,000,000USD
    Minority Interest-7,000,000USD-8,000,000USD-10,000,000USD-9,000,000USD-7,000,000USD6,000,000USD21,000,000USD21,000,000USD
    Selling And Marketing Expenses—2,100,000,000USD2,200,000,000USD2,000,000,000USD2,100,000,000USD1,800,000,000USD—1,100,000,000USD
    Non Operating Income Net Other———-2,596,000,000USD-2,551,000,000USD-5,685,000,000USD-3,048,000,000USD-42,000,000USD
    Net Income Applicable To Common Shares———11,836,000,000USD11,542,000,000USD4,616,000,000USD7,882,000,000USD5,687,000,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USDQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USD
    Total Assets135,115,000,000USD136,463,000,000USD133,960,000,000USD133,898,000,000USD137,182,000,000USD136,165,000,000USD135,161,000,000USD143,422,000,000USD
    Cash And Equivalents6,569,000,000USD9,391,000,000USD——————
    Long Term Investments266,000,000USD268,000,000USD268,000,000USD291,000,000USD310,000,000USD287,000,000USD279,000,000USD267,000,000USD
    Total Current Assets33,669,000,000USD33,529,000,000USD29,062,000,000USD28,539,000,000USD29,261,000,000USD27,675,000,000USD25,582,000,000USD27,785,000,000USD
    Other Current Assets8,149,000,000USD—6,265,000,000USD5,161,000,000USD5,197,000,000USD5,496,000,000USD4,927,000,000USD4,578,000,000USD
    Other Non Current Assets10,726,000,000USD10,536,000,000USD——————
    Total Liabilities141,003,000,000USD143,075,000,000USD——————
    Total Current Liabilities41,642,000,000USD42,100,000,000USD43,289,000,000USD39,391,000,000USD39,767,000,000USD36,403,000,000USD38,749,000,000USD43,062,000,000USD
    Other Non Current Liabilities34,603,000,000USD34,111,000,000USD——————
    Total Stockholder Equity-5,935,000,000USD-6,656,000,000USD-3,228,000,000USD-2,599,000,000USD-138,000,000USD1,462,000,000USD3,364,000,000USD6,071,000,000USD
    Total Equity Including Noncontrolling Interest-5,888,000,000USD-6,612,000,000USD——————
    Short Long Term Debt8,341,000,000USD—8,555,000,000USD5,772,000,000USD7,522,000,000USD5,362,000,000USD6,804,000,000USD12,570,000,000USD
    Long Term Debt62,481,000,000USD64,532,000,000USD58,941,000,000USD62,971,000,000USD62,959,000,000USD64,527,000,000USD60,340,000,000USD58,509,000,000USD
    Net Receivables13,824,000,000USD12,479,000,000USD12,589,000,000USD12,769,000,000USD12,637,000,000USD12,477,000,000USD10,919,000,000USD11,472,000,000USD
    Inventory5,127,000,000USD5,049,000,000USD4,951,000,000USD4,938,000,000USD4,960,000,000USD4,526,000,000USD4,181,000,000USD4,450,000,000USD
    Property Plant Equipment Net5,796,000,000USD5,687,000,000USD6,365,000,000USD5,483,000,000USD5,283,000,000USD5,237,000,000USD5,134,000,000USD5,141,000,000USD
    Goodwill35,519,000,000USD35,570,000,000USD——————
    Intangible Assets49,139,000,000USD50,873,000,000USD52,641,000,000USD54,315,000,000USD57,031,000,000USD58,489,000,000USD60,068,000,000USD66,646,000,000USD
    Accounts Payable33,301,000,000USD33,774,000,000USD34,422,000,000USD33,362,000,000USD31,832,000,000USD30,959,000,000USD31,910,000,000USD30,398,000,000USD
    Short Term Debt0USD—8,555,000,000USD5,772,000,000USD7,522,000,000USD5,362,000,000USD6,804,000,000USD12,570,000,000USD
    Common Stock18,000,000USD—18,000,000USD18,000,000USD18,000,000USD18,000,000USD18,000,000USD18,000,000USD
    Retained Earnings-17,333,000,000USD-17,872,000,000USD-15,493,000,000USD-14,234,000,000USD-11,503,000,000USD-9,527,000,000USD-7,900,000,000USD-4,964,000,000USD
    Accumulated Other Comprehensive Income-1,158,000,000USD-1,153,000,000USD-1,144,000,000USD-1,574,000,000USD-1,538,000,000USD-1,742,000,000USD-1,925,000,000USD-2,334,000,000USD
    Total Liab——137,188,000,000USD136,497,000,000USD137,320,000,000USD134,703,000,000USD131,797,000,000USD137,351,000,000USD
    Other Current Liab——312,000,000USD257,000,000USD413,000,000USD82,000,000USD35,000,000USD94,000,000USD
    Capital Stock——18,000,000USD18,000,000USD18,000,000USD18,000,000USD18,000,000USD18,000,000USD
    Good Will——35,640,000,000USD35,626,000,000USD35,638,000,000USD35,285,000,000USD34,956,000,000USD35,295,000,000USD
    Other Assets——228,000,000USD————143,422,000,000USD
    Cash——5,229,000,000USD5,629,000,000USD6,467,000,000USD5,175,000,000USD5,524,000,000USD7,257,000,000USD
    Cash And Short Term Investments——5,257,000,000USD5,671,000,000USD6,467,000,000USD5,176,000,000USD5,555,000,000USD7,285,000,000USD
    Net Debt——63,645,000,000USD63,114,000,000USD64,014,000,000USD64,714,000,000USD62,317,000,000USD63,822,000,000USD
    Short Long Term Debt Total——68,874,000,000USD68,743,000,000USD70,481,000,000USD69,889,000,000USD67,841,000,000USD71,079,000,000USD
    Short Term Investments——28,000,000USD42,000,000USD0USD1,000,000USD31,000,000USD28,000,000USD
    Property Plant Equipment Gross——13,530,000,000USD13,229,000,000USD12,934,000,000USD12,571,000,000USD12,267,000,000USD12,279,000,000USD
    Common Stock Shares Outstanding——1,774,000,000shares1,772,000,000shares1,772,000,000shares1,772,000,000shares1,773,000,000shares1,772,000,000shares
    Non Current Assets Total——104,898,000,000USD105,359,000,000USD107,921,000,000USD108,490,000,000USD109,579,000,000USD115,637,000,000USD
    Non Current Liabilities Total——93,899,000,000USD97,106,000,000USD97,553,000,000USD98,300,000,000USD93,048,000,000USD94,289,000,000USD
    Non Current Liabilities Other——30,795,000,000USD31,655,000,000USD32,040,000,000USD31,191,000,000USD27,634,000,000USD33,031,000,000USD
    Non Currrent Assets Other——9,953,000,000USD9,644,000,000USD9,659,000,000USD9,192,000,000USD9,142,000,000USD8,288,000,000USD
    Net Working Capital——-14,227,000,000USD-10,852,000,000USD-10,506,000,000USD-8,728,000,000USD-13,167,000,000USD-15,277,000,000USD
    Unclassified Current Liabilities——-8,555,000,000USD-5,772,000,000USD-7,522,000,000USD-5,362,000,000USD-6,804,000,000USD-12,570,000,000USD
    Unclassified Non Current Liabilities——4,163,000,000USD2,480,000,000USD2,554,000,000USD2,582,000,000USD5,074,000,000USD2,749,000,000USD
    Unclassified Equity——13,373,000,000USD13,173,000,000USD12,867,000,000USD12,695,000,000USD13,153,000,000USD13,333,000,000USD
    Current Deferred Revenue———————-30,398,000,000USD
    Unclassified Non Current Assets———————-143,422,000,000USD
    SourceDisclosureDeterministicFinalDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Total Assets133,960,000,000USD135,161,000,000USD134,711,000,000USD138,805,000,000USD146,529,000,000USD150,565,000,000USD89,115,000,000USD59,352,000,000USD
    Intangible Assets52,641,000,000USD60,068,000,000USD55,610,000,000USD67,439,000,000USD75,951,000,000USD82,876,000,000USD18,649,000,000USD21,233,000,000USD
    Other Current Assets6,265,000,000USD4,927,000,000USD4,932,000,000USD4,401,000,000USD4,993,000,000USD3,562,000,000USD2,354,000,000USD1,895,000,000USD
    Total Liab137,188,000,000USD131,797,000,000USD124,314,000,000USD121,518,000,000USD131,093,000,000USD137,468,000,000USD97,287,000,000USD67,798,000,000USD
    Total Stockholder Equity-3,228,000,000USD3,364,000,000USD10,397,000,000USD17,287,000,000USD15,436,000,000USD13,097,000,000USD-8,172,000,000USD-8,446,000,000USD
    Other Current Liab30,948,000,000USD29,000,000,000USD26,962,000,000USD22,302,000,000USD19,639,000,000USD17,708,000,000USD10,380,000,000USD10,385,000,000USD
    Common Stock18,000,000USD18,000,000USD18,000,000USD18,000,000USD18,000,000USD18,000,000USD18,000,000USD18,000,000USD
    Capital Stock18,000,000USD18,000,000USD18,000,000USD18,000,000USD18,000,000USD18,000,000USD18,000,000USD18,000,000USD
    Retained Earnings-15,493,000,000USD-7,900,000,000USD-1,000,000,000USD4,784,000,000USD3,127,000,000USD1,055,000,000USD4,717,000,000USD3,368,000,000USD
    Good Will35,640,000,000USD34,956,000,000USD32,293,000,000USD32,156,000,000USD32,379,000,000USD33,124,000,000USD15,604,000,000USD15,663,000,000USD
    Other Assets228,000,000USD——4,834,000,000USD4,081,000,000USD5,144,000,000USD1,913,000,000USD1,208,000,000USD
    Cash5,229,000,000USD5,524,000,000USD12,814,000,000USD9,201,000,000USD9,746,000,000USD8,449,000,000USD39,924,000,000USD7,289,000,000USD
    Cash And Short Term Investments5,257,000,000USD5,555,000,000USD12,816,000,000USD9,229,000,000USD9,830,000,000USD8,479,000,000USD39,924,000,000USD8,061,000,000USD
    Total Current Assets29,062,000,000USD25,582,000,000USD33,002,000,000USD28,463,000,000USD27,928,000,000USD24,173,000,000USD49,519,000,000USD16,945,000,000USD
    Total Current Liabilities43,289,000,000USD38,749,000,000USD37,841,000,000USD29,538,000,000USD35,194,000,000USD28,661,000,000USD15,585,000,000USD17,239,000,000USD
    Net Debt63,839,000,000USD62,317,000,000USD47,306,000,000USD54,990,000,000USD67,829,000,000USD78,614,000,000USD27,164,000,000USD33,021,000,000USD
    Short Term Debt8,749,000,000USD6,804,000,000USD7,191,000,000USD4,302,000,000USD12,673,000,000USD8,677,000,000USD3,753,000,000USD5,308,000,000USD
    Short Long Term Debt8,555,000,000USD6,804,000,000USD7,191,000,000USD4,136,000,000USD12,495,000,000USD8,502,000,000USD3,753,000,000USD5,308,000,000USD
    Short Long Term Debt Total69,068,000,000USD67,841,000,000USD60,120,000,000USD64,191,000,000USD77,575,000,000USD87,063,000,000USD67,088,000,000USD40,310,000,000USD
    Long Term Debt58,941,000,000USD60,340,000,000USD52,194,000,000USD59,135,000,000USD64,189,000,000USD77,554,000,000USD62,975,000,000USD35,002,000,000USD
    Long Term Investments268,000,000USD279,000,000USD304,000,000USD241,000,000USD277,000,000USD293,000,000USD93,000,000USD1,420,000,000USD
    Short Term Investments28,000,000USD31,000,000USD2,000,000USD28,000,000USD84,000,000USD30,000,000USD0USD772,000,000USD
    Net Receivables12,589,000,000USD10,919,000,000USD11,155,000,000USD11,254,000,000USD9,977,000,000USD8,822,000,000USD5,428,000,000USD5,384,000,000USD
    Inventory4,951,000,000USD4,181,000,000USD4,099,000,000USD3,579,000,000USD3,128,000,000USD3,310,000,000USD1,813,000,000USD1,605,000,000USD
    Accounts Payable3,592,000,000USD2,945,000,000USD3,688,000,000USD2,934,000,000USD2,882,000,000USD2,276,000,000USD1,452,000,000USD1,546,000,000USD
    Property Plant Equipment Net6,365,000,000USD5,134,000,000USD4,989,000,000USD4,935,000,000USD5,110,000,000USD5,248,000,000USD2,962,000,000USD2,883,000,000USD
    Property Plant Equipment Gross13,530,000,000USD12,267,000,000USD11,635,000,000USD10,986,000,000USD10,727,000,000USD5,248,000,000USD2,962,000,000USD2,883,000,000USD
    Accumulated Other Comprehensive Income-1,144,000,000USD-1,925,000,000USD-2,305,000,000USD-2,199,000,000USD-2,899,000,000USD-3,117,000,000USD-3,596,000,000USD-2,480,000,000USD
    Common Stock Shares Outstanding1,774,000,000shares1,773,000,000shares1,773,000,000shares1,778,000,000shares1,777,000,000shares1,673,000,000shares1,484,000,000shares1,546,000,000shares
    Non Current Assets Total104,898,000,000USD109,579,000,000USD101,709,000,000USD110,342,000,000USD118,601,000,000USD126,392,000,000USD39,596,000,000USD42,407,000,000USD
    Non Current Liabilities Total93,899,000,000USD93,048,000,000USD86,473,000,000USD91,980,000,000USD95,899,000,000USD108,807,000,000USD81,702,000,000USD50,559,000,000USD
    Non Current Liabilities Other30,795,000,000USD27,634,000,000USD28,607,000,000USD30,655,000,000USD28,701,000,000USD27,607,000,000USD17,597,000,000USD14,490,000,000USD
    Non Currrent Assets Other9,953,000,000USD9,142,000,000USD8,513,000,000USD5,571,000,000USD4,884,000,000USD4,851,000,000USD2,288,000,000USD1,208,000,000USD
    Net Working Capital-14,227,000,000USD-13,167,000,000USD-4,839,000,000USD-1,075,000,000USD-7,266,000,000USD-4,488,000,000USD33,934,000,000USD-294,000,000USD
    Unclassified Current Liabilities-8,555,000,000USD-6,804,000,000USD-7,191,000,000USD-4,136,000,000USD-12,495,000,000USD-8,502,000,000USD-3,753,000,000USD-5,308,000,000USD
    Unclassified Non Current Liabilities4,163,000,000USD5,074,000,000USD5,672,000,000USD-31,716,000,000USD-30,982,000,000USD-30,401,000,000USD-18,476,000,000USD-15,557,000,000USD
    Unclassified Equity13,373,000,000USD13,153,000,000USD——————
    Current Deferred Revenue——-3,688,000,000USD—————
    Additional Paid In Capital——20,180,000,000USD19,245,000,000USD18,305,000,000USD17,384,000,000USD15,193,000,000USD14,756,000,000USD
    Treasury Stock——-6,533,000,000USD-4,594,000,000USD-3,143,000,000USD-2,264,000,000USD-24,504,000,000USD-24,108,000,000USD
    Deferred Long Term Liab———2,190,000,000USD3,009,000,000USD3,646,000,000USD1,130,000,000USD1,067,000,000USD
    Other Liab———31,716,000,000USD30,982,000,000USD30,401,000,000USD18,476,000,000USD15,557,000,000USD
    Net Tangible Assets———-82,341,000,000USD-96,202,000,000USD-102,924,000,000USD-42,425,000,000USD-45,342,000,000USD
    Unclassified Non Current Assets———-4,834,000,000USD-4,081,000,000USD-5,144,000,000USD-1,913,000,000USD-1,208,000,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow YTD

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USD
    Net Income4,313,000,000USD
    Depreciation3,819,000,000USD
    Stock Based Compensation610,000,000USD
    Deferred Income Tax-58,000,000USD
    Other Non Cash Items5,008,000,000USD
    Unclassified Operating Cash Flow-4,088,000,000USD
    Change To Account Receivables-1,282,000,000USD
    Change To Inventory-327,000,000USD
    Change To Liabilities-392,000,000USD
    Change In Working Capital-2,339,000,000USD
    Operating Cash Flow7,265,000,000USD
    Capital Expenditures-587,000,000USD
    Net Investments-1,090,000,000USD
    Other Investing Activities-94,000,000USD
    Unclassified Investing Cash Flow0USD
    Investing Cash Flow-1,771,000,000USD
    Net Debt Issuance3,492,000,000USD
    Net Common Stock Issuance-1,498,000,000USD
    Common Dividends Paid-6,156,000,000USD
    Other Financing Activities27,000,000USD
    Unclassified Financing Cash Flow0USD
    Financing Cash Flow-4,135,000,000USD
    Effect Of Forex Changes On Cash-19,000,000USD
    Change In Cash1,340,000,000USD
    End Cash Flow6,569,000,000USD
    SourceDisclosureDeterministicFinal

    Cash flow Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ2 20242024-06-30 · USDQ1 20242024-03-31 · USD
    Depreciation1,936,000,000USD1,987,000,000USD2,063,000,000USD2,050,000,000USD2,039,000,000USD2,102,000,000USD2,131,000,000USD2,074,000,000USD
    Stock Based Compensation444,000,000USD157,000,000USD209,000,000USD179,000,000USD410,000,000USD674,000,000USD218,000,000USD348,000,000USD
    Deferred Income Tax137,000,000USD———————
    Other Non Cash Items22,000,000USD2,126,000,000USD1,229,000,000USD2,817,000,000USD505,000,000USD1,150,000,000USD1,947,000,000USD401,000,000USD
    Change To Account Receivables87,000,000USD162,000,000USD-156,000,000USD-17,000,000USD-1,479,000,000USD387,000,000USD178,000,000USD-702,000,000USD
    Change To Inventory-184,000,000USD-25,000,000USD2,000,000USD-56,000,000USD-155,000,000USD-128,000,000USD-52,000,000USD-75,000,000USD
    Change To Liabilities-1,594,000,000USD———————
    Change In Working Capital-1,841,000,000USD-473,000,000USD3,142,000,000USD-562,000,000USD-2,580,000,000USD-397,000,000USD-3,382,000,000USD247,000,000USD
    Operating Cash Flow3,829,000,000USD———————
    Capital Expenditures-265,000,000USD-329,000,000USD504,000,000USD-269,000,000USD-235,000,000USD-291,000,000USD-241,000,000USD-193,000,000USD
    Net Investments-266,000,000USD———————
    Other Investing Activities43,000,000USD———————
    Unclassified Investing Cash Flow-86,000,000USD-1,161,000,000USD4,534,000,000USD236,000,000USD219,000,000USD94,000,000USD246,000,000USD199,000,000USD
    Investing Cash Flow-574,000,000USD———————
    Net Debt Issuance7,492,000,000USD———————
    Net Common Stock Issuance-1,489,000,000USD———————
    Common Dividends Paid-3,086,000,000USD———————
    Other Financing Activities2,000,000USD———————
    Unclassified Financing Cash Flow-2,000,000,000USD48,000,000USD-977,000,000USD———-3,348,000,000USD14,863,000,000USD
    Financing Cash Flow919,000,000USD———————
    Effect Of Forex Changes On Cash-12,000,000USD———————
    Change In Cash4,162,000,000USD-400,000,000USD-838,000,000USD1,292,000,000USD-349,000,000USD-1,733,000,000USD-4,937,000,000USD5,253,000,000USD
    End Cash Flow9,391,000,000USD———————
    Net Income—1,816,000,000USD188,000,000USD941,000,000USD1,289,000,000USD4,286,000,000USD1,373,000,000USD1,359,000,000USD
    Total Cash From Operating Activities—5,218,000,000USD7,024,000,000USD5,153,000,000USD1,635,000,000USD7,048,000,000USD2,271,000,000USD4,040,000,000USD
    Free Cash Flow—4,889,000,000USD7,528,000,000USD4,884,000,000USD1,400,000,000USD6,757,000,000USD2,030,000,000USD3,847,000,000USD
    Investments—28,000,000USD-3,264,000,000USD-1,181,000,000USD-735,000,000USD-1,874,000,000USD-1,102,000,000USD-9,588,000,000USD
    Total Cashflows From Investing Activities—-1,463,000,000USD-3,264,000,000USD-1,181,000,000USD-735,000,000USD-1,874,000,000USD-1,102,000,000USD-9,588,000,000USD
    Net Borrowings—-1,299,000,000USD-1,775,000,000USD209,000,000USD2,561,000,000USD-3,762,000,000USD——
    Total Cash From Financing Activities—-4,166,000,000USD-4,590,000,000USD-2,710,000,000USD-1,258,000,000USD-6,861,000,000USD-6,097,000,000USD10,819,000,000USD
    Dividends Paid—-2,911,000,000USD-2,911,000,000USD-2,910,000,000USD-2,925,000,000USD-2,752,000,000USD-2,750,000,000USD-2,772,000,000USD
    Sale Purchase Of Stock—-3,000,000USD4,000,000USD-12,000,000USD-961,000,000USD-358,000,000USD-9,000,000USD-1,324,000,000USD
    Begin Period Cash Flow—5,629,000,000USD6,467,000,000USD5,175,000,000USD5,524,000,000USD7,257,000,000USD18,067,000,000USD12,814,000,000USD
    End Period Cash Flow—5,229,000,000USD5,629,000,000USD6,467,000,000USD5,175,000,000USD5,524,000,000USD13,130,000,000USD18,067,000,000USD
    Other Cashflows From Investing Activities—-1,000,000USD-5,038,000,000USD33,000,000USD16,000,000USD197,000,000USD-5,000,000USD-6,000,000USD
    Other Cashflows From Financing Activities—-1,000,000USD1,069,000,000USD3,000,000USD67,000,000USD11,000,000USD10,000,000USD52,000,000USD
    Unclassified Operating Cash Flow—-395,000,000USD193,000,000USD-272,000,000USD-28,000,000USD-767,000,000USD—-389,000,000USD
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Net Income4,226,000,000USD4,286,000,000USD4,820,000,000USD11,845,000,000USD11,549,000,000USD4,622,000,000USD7,882,000,000USD5,687,000,000USD
    Depreciation8,139,000,000USD8,386,000,000USD8,698,000,000USD8,467,000,000USD8,521,000,000USD6,471,000,000USD2,017,000,000USD1,765,000,000USD
    Stock Based Compensation955,000,000USD911,000,000USD747,000,000USD671,000,000USD692,000,000USD753,000,000USD430,000,000USD421,000,000USD
    Other Non Cash Items8,604,000,000USD9,454,000,000USD8,650,000,000USD6,149,000,000USD4,235,000,000USD7,961,000,000USD3,624,000,000USD6,256,000,000USD
    Change To Account Receivables-1,490,000,000USD207,000,000USD66,000,000USD-1,455,000,000USD-1,321,000,000USD-929,000,000USD-74,000,000USD-591,000,000USD
    Change To Inventory-234,000,000USD-319,000,000USD-417,000,000USD-686,000,000USD-142,000,000USD-40,000,000USD-231,000,000USD-226,000,000USD
    Change In Working Capital-2,362,000,000USD-2,782,000,000USD2,813,000,000USD-258,000,000USD-1,322,000,000USD106,000,000USD-1,329,000,000USD-1,126,000,000USD
    Total Cash From Operating Activities19,030,000,000USD18,806,000,000USD22,839,000,000USD24,943,000,000USD22,777,000,000USD17,588,000,000USD13,324,000,000USD13,427,000,000USD
    Capital Expenditures-1,214,000,000USD-974,000,000USD-777,000,000USD-695,000,000USD-787,000,000USD-798,000,000USD-552,000,000USD-638,000,000USD
    Free Cash Flow17,816,000,000USD17,832,000,000USD22,062,000,000USD24,248,000,000USD21,990,000,000USD16,790,000,000USD12,772,000,000USD12,789,000,000USD
    Investments41,000,000USD-20,820,000,000USD-2,009,000,000USD-447,000,000USD-1,398,000,000USD114,000,000USD981,000,000USD-368,000,000USD
    Total Cashflows From Investing Activities-6,643,000,000USD-20,820,000,000USD-2,009,000,000USD-623,000,000USD-2,344,000,000USD-37,557,000,000USD596,000,000USD-1,006,000,000USD
    Net Borrowings-304,000,000USD7,350,000,000USD-4,149,000,000USD-12,433,000,000USD-8,414,000,000USD-2,703,000,000USD25,823,000,000USD3,189,000,000USD
    Total Cash From Financing Activities-12,724,000,000USD-5,211,000,000USD-17,222,000,000USD-24,803,000,000USD-19,039,000,000USD-11,501,000,000USD18,708,000,000USD-14,396,000,000USD
    Dividends Paid-11,657,000,000USD-11,025,000,000USD-10,539,000,000USD-10,043,000,000USD-9,261,000,000USD-7,716,000,000USD-6,366,000,000USD-5,580,000,000USD
    Sale Purchase Of Stock-980,000,000USD-1,708,000,000USD-1,972,000,000USD-1,487,000,000USD-934,000,000USD-978,000,000USD-629,000,000USD-12,014,000,000USD
    Change In Cash-295,000,000USD-7,290,000,000USD3,613,000,000USD-545,000,000USD1,297,000,000USD-31,475,000,000USD32,635,000,000USD-2,014,000,000USD
    Begin Period Cash Flow5,524,000,000USD12,814,000,000USD9,201,000,000USD9,746,000,000USD8,449,000,000USD39,924,000,000USD7,289,000,000USD9,303,000,000USD
    End Period Cash Flow5,229,000,000USD5,524,000,000USD12,814,000,000USD9,201,000,000USD9,746,000,000USD8,449,000,000USD39,924,000,000USD7,289,000,000USD
    Other Cashflows From Investing Activities-5,266,000,000USD-2,835,000,000USD13,000,000USD519,000,000USD-159,000,000USD-36,873,000,000USD167,000,000USD-736,000,000USD
    Other Cashflows From Financing Activities68,000,000USD172,000,000USD-562,000,000USD1,160,000,000USD-674,000,000USD-333,000,000USD-552,000,000USD-31,000,000USD
    Unclassified Operating Cash Flow-532,000,000USD-1,449,000,000USD-2,889,000,000USD-1,931,000,000USD-898,000,000USD-2,325,000,000USD700,000,000USD424,000,000USD
    Unclassified Investing Cash Flow-204,000,000USD3,809,000,000USD764,000,000USD————736,000,000USD
    Unclassified Financing Cash Flow149,000,000USD——-2,000,000,000USD244,000,000USD229,000,000USD432,000,000USD—
    Change To Liabilities———2,147,000,000USD338,000,000USD941,000,000USD-1,121,000,000USD190,000,000USD
    Cash And Cash Equivalents Changes———-483,000,000USD1,297,000,000USD-31,475,000,000USD32,635,000,000USD-2,014,000,000USD
    Exchange Rate Changes————-97,000,000USD-5,000,000USD7,000,000USD-39,000,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Operating metrics

    Mid- and Late-Stage Development Pipeline

    Period endPeriodValueUnitSource
    2026-06-30instant60countDisclosure

    Total Development Pipeline

    Period endPeriodValueUnitSource
    2026-06-30instant90countDisclosure

    Revenue breakdown

    PeriodDimensionBusiness / regionRevenueCurrencySource
    Q1 2026Quarterly · 2026-03-31ProductBotox Cosmetic668,000,000USDDisclosure
    Q1 2026Quarterly · 2026-03-31ProductBotox Therapeutic1,009,000,000USDDisclosure
    Q1 2026Quarterly · 2026-03-31ProductElahere198,000,000USDDisclosure
    Q1 2026Quarterly · 2026-03-31ProductEpkinly83,000,000USDDisclosure
    Q1 2026Quarterly · 2026-03-31ProductHUMIRA688,000,000USDDisclosure
    Q1 2026Quarterly · 2026-03-31ProductImbruvica556,000,000USDDisclosure
    Q1 2026Quarterly · 2026-03-31ProductJuvederm Collection232,000,000USDDisclosure
    Q1 2026Quarterly · 2026-03-31ProductLinzess Constella283,000,000USDDisclosure
    Q1 2026Quarterly · 2026-03-31ProductMAVYRET351,000,000USDDisclosure
    Q1 2026Quarterly · 2026-03-31ProductOther Aesthetics286,000,000USDDisclosure
    Q1 2026Quarterly · 2026-03-31ProductOther Neuroscience510,000,000USDDisclosure
    Q1 2026Quarterly · 2026-03-31ProductOther Products1,025,000,000USDDisclosure
    Q1 2026Quarterly · 2026-03-31ProductQulipta296,000,000USDDisclosure
    Q1 2026Quarterly · 2026-03-31ProductRINVOQ2,119,000,000USDDisclosure
    Q1 2026Quarterly · 2026-03-31ProductSKYRIZI4,483,000,000USDDisclosure
    Q1 2026Quarterly · 2026-03-31ProductUbrelvy339,000,000USDDisclosure
    Q1 2026Quarterly · 2026-03-31ProductVENCLEXTA770,000,000USDDisclosure
    Q1 2026Quarterly · 2026-03-31ProductVraylar905,000,000USDDisclosure
    Q1 2026Quarterly · 2026-03-31ProductVyalev201,000,000USDDisclosure
    Q4 2025Quarterly · 2025-12-31ProductAlphagan Combigan54,000,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31ProductBotox Cosmetic717,000,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31ProductBotox Therapeutic990,000,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31ProductDuodopa92,000,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31ProductElahere182,000,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31ProductEpkinly81,000,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31ProductHUMIRA1,246,000,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31ProductImbruvica671,000,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31ProductJuvederm Collection249,000,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31ProductLinzess Constella175,000,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31ProductLumigan Ganfort104,000,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31ProductMAVYRET324,000,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31ProductOther Aesthetics320,000,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31ProductOther Eye Care294,000,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31ProductOther Neuroscience452,000,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31ProductOther Products617,000,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31ProductOzurdex128,000,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31ProductQulipta288,000,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31ProductRINVOQ2,374,000,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31ProductSKYRIZI5,006,000,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31ProductUbrelvy339,000,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31ProductVENCLEXTA710,000,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31ProductVraylar1,022,000,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31ProductVyalev183,000,000USDLegacy provider
    FY 2025Yearly · 2025-12-31GeographyAustralia459,000,000USDDisclosure
    FY 2025Yearly · 2025-12-31GeographyBR478,000,000USDDisclosure
    FY 2025Yearly · 2025-12-31GeographyCanada1,222,000,000USDDisclosure
    FY 2025Yearly · 2025-12-31GeographyChina1,006,000,000USDDisclosure
    FY 2025Yearly · 2025-12-31GeographyES609,000,000USDDisclosure
    FY 2025Yearly · 2025-12-31GeographyFrance806,000,000USDDisclosure
    FY 2025Yearly · 2025-12-31GeographyGermany1,738,000,000USDDisclosure
    FY 2025Yearly · 2025-12-31GeographyItaly580,000,000USDDisclosure
    FY 2025Yearly · 2025-12-31GeographyJapan1,274,000,000USDDisclosure
    FY 2025Yearly · 2025-12-31GeographyOther Countries5,759,000,000USDDisclosure
    FY 2025Yearly · 2025-12-31GeographyUnited Kingdom626,000,000USDDisclosure
    FY 2025Yearly · 2025-12-31GeographyUnited States46,603,000,000USDDisclosure
    FY 2025Yearly · 2025-12-31ProductAlphagan Combigan197,000,000USDDisclosure
    FY 2025Yearly · 2025-12-31ProductBotox Cosmetic2,602,000,000USDDisclosure
    FY 2025Yearly · 2025-12-31ProductBotox Therapeutic3,769,000,000USDDisclosure
    FY 2025Yearly · 2025-12-31ProductDuodopa381,000,000USDDisclosure
    FY 2025Yearly · 2025-12-31ProductElahere690,000,000USDDisclosure
    FY 2025Yearly · 2025-12-31ProductEpkinly271,000,000USDDisclosure
    FY 2025Yearly · 2025-12-31ProductHUMIRA4,540,000,000USDDisclosure
    FY 2025Yearly · 2025-12-31ProductImbruvica2,869,000,000USDDisclosure
    FY 2025Yearly · 2025-12-31ProductJuvederm Collection993,000,000USDDisclosure
    FY 2025Yearly · 2025-12-31ProductLinzess Constella907,000,000USDDisclosure
    FY 2025Yearly · 2025-12-31ProductLumigan Ganfort410,000,000USDDisclosure
    FY 2025Yearly · 2025-12-31ProductMAVYRET1,317,000,000USDDisclosure
    FY 2025Yearly · 2025-12-31ProductOther Aesthetics1,265,000,000USDDisclosure
    FY 2025Yearly · 2025-12-31ProductOther Eye Care1,009,000,000USDDisclosure
    FY 2025Yearly · 2025-12-31ProductOther Neuroscience1,752,000,000USDDisclosure
    FY 2025Yearly · 2025-12-31ProductOther Products2,627,000,000USDDisclosure
    FY 2025Yearly · 2025-12-31ProductOzurdex493,000,000USDDisclosure
    FY 2025Yearly · 2025-12-31ProductQulipta1,036,000,000USDDisclosure
    FY 2025Yearly · 2025-12-31ProductRINVOQ8,304,000,000USDDisclosure
    FY 2025Yearly · 2025-12-31ProductSKYRIZI17,562,000,000USDDisclosure
    FY 2025Yearly · 2025-12-31ProductUbrelvy1,271,000,000USDDisclosure
    FY 2025Yearly · 2025-12-31ProductVENCLEXTA2,792,000,000USDDisclosure
    FY 2025Yearly · 2025-12-31ProductVraylar3,621,000,000USDDisclosure
    FY 2025Yearly · 2025-12-31ProductVyalev482,000,000USDDisclosure
    Q3 2025Quarterly · 2025-09-30ProductAlphagan Combigan47,000,000USDDisclosure
    Q3 2025Quarterly · 2025-09-30ProductBotox Cosmetic637,000,000USDDisclosure
    Q3 2025Quarterly · 2025-09-30ProductBotox Therapeutic985,000,000USDDisclosure
    Q3 2025Quarterly · 2025-09-30ProductDuodopa96,000,000USDDisclosure
    Q3 2025Quarterly · 2025-09-30ProductElahere170,000,000USDDisclosure
    Q3 2025Quarterly · 2025-09-30ProductEpkinly69,000,000USDDisclosure
    Q3 2025Quarterly · 2025-09-30ProductHUMIRA993,000,000USDDisclosure
    Q3 2025Quarterly · 2025-09-30ProductImbruvica706,000,000USDDisclosure
    Q3 2025Quarterly · 2025-09-30ProductJuvederm Collection253,000,000USDDisclosure
    Q3 2025Quarterly · 2025-09-30ProductLinzess Constella326,000,000USDDisclosure
    Q3 2025Quarterly · 2025-09-30ProductLumigan Ganfort97,000,000USDDisclosure
    Q3 2025Quarterly · 2025-09-30ProductMAVYRET312,000,000USDDisclosure
    Q3 2025Quarterly · 2025-09-30ProductOther Aesthetics303,000,000USDDisclosure
    Q3 2025Quarterly · 2025-09-30ProductOther Eye Care248,000,000USDDisclosure
    Q3 2025Quarterly · 2025-09-30ProductOther Neuroscience425,000,000USDDisclosure
    Q3 2025Quarterly · 2025-09-30ProductOther Products660,000,000USDDisclosure
    Q3 2025Quarterly · 2025-09-30ProductOzurdex117,000,000USDDisclosure
    Q3 2025Quarterly · 2025-09-30ProductQulipta288,000,000USDDisclosure
    Q3 2025Quarterly · 2025-09-30ProductRINVOQ2,184,000,000USDDisclosure
    Q3 2025Quarterly · 2025-09-30ProductSKYRIZI4,708,000,000USDDisclosure
    Q3 2025Quarterly · 2025-09-30ProductUbrelvy354,000,000USDDisclosure

    Periods follow company fiscal calendars. Quarterly, annual and year-to-date amounts are shown separately. Missing values are not zero. Data may be delayed, incomplete or corrected; follow the disclosure links to verify figures.